产品名称：**CL-387785**
产品别名：**CL-387785**

生物活性：

Description	CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC_{50} of 370 pM.
IC_{50} & Target	EGFR
	370 pM (IC_{50})

Solvent&Solubility

In Vitro:

DMSO : 13.67 mg/mL (35.86 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6231 mL	13.1154 mL	26.2309 mL
	5 mM	0.5246 mL	2.6231 mL	5.2462 mL
	10 mM	0.2623 mL	1.3115 mL	2.6231 mL

*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

References

[1]. Discafani CM, et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol. 1999 Apr 15;57(8):917-25.

[2]. Sweeney WE, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000 Jan;57(1):33-40.

[3]. Greulich H, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov;2(11):e313.

[4]. Kobayashi S, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15;65(16):7096-101.

源叶生物